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1810The use of total bilirubin as a component of the MELD score is
comprehensible if applying the score to patients with liver cirrhosis,
as the complex distortion of hepatic lobule results in elevation of
both indirect and direct bilirubin. However, liver cirrhosis as an
end-stage organ failure is a rare ﬁnding in patients with HF
nowadays (8). The underlying mechanism responsible for abnormal
liver function tests in patients with HF is primarily liver congestion
due to backward right HF. This results predominantly in mild
elevation of cholestatic markers (2). Thus, direct bilirubin is
probably a more speciﬁc indicator of liver dysfunction in patients
with chronic HF than total bilirubin is, especially as total bilirubin
might be elevated due to other reasons than chronic HF. Therefore,
we suggest modifying the MELD score for HF patients by using
direct bilirubin instead of total bilirubin.
As the investigators themselves state, there cannot be established
any causality between a higher MELD score and mortality and/
or need for cardiac transplantation. Beyond the reported association
between markers of right heart function and the MELD score, it
would be helpful to provide information about the medication of
patients with a higher MELD score. What if the score reﬂected
sicker patients with more medication and a variety of subsequent
drug-liver interactions and only to a lesser extent the suggested
congestion due to HF?
In accordance with Eisen (9), we think that it remains to be
elucidated whether optimization of medical therapy can lower the
MELD score. Especially interventions targeting splanchnic
congestion (e.g., intensiﬁed diuretic therapy) are eagerly awaited and
should be evaluated with regard to the stability of the MELD score.*Miroslava Valentova, MD
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Coll Cardiol 2013;61:2262–3.ReplyCardiac Hepatopathy Versus
End-Stage Liver Disease
Two Different Entities
We thank Dr. Valentova and colleagues for their insightful
comments on our recent study (1) of liver function abnormalities
characterized by various MELD (Model of End Stage Liver
Disease) scoring systems in patients evaluated for heart trans-
plantation (HTx). On the basis of our analysis, utilization of
MELD scoring systems may improve our risk prediction on the
basis of a composite evaluation of end-organ dysfunction including
liver and renal functional abnormalities. Of note, the use of the
standard MELD score is limited to patients not on oral anti-
coagulation due to the impact of vitamin K antagonists on the
international normalized ratio (INR), which is an essential
component of the standard MELD score. For that reason, we
analyzed both patients on and off oral anticoagulants separately
and included the modiﬁed MELD-XI score, which allows char-
acterization of patients on vitamin K antagonists.
Dr. Valentova and colleagues also state that in patients with
liver cirrhosis, the use of total bilirubin is most appropriate and
that liver cirrhosis is a rare ﬁnding in patients with HF. This does
not reﬂect our experience, as the degree of liver cirrhosis is a
frequent concern in our population of patients evaluated for HTx;
in particular, in patients with longstanding right and biventricular
heart failure, patients on left ventricular assist device support and
patients with congenital heart disease after, for example, Fontan
repair. At our center, we performed liver biopsies in more than 5%
of all transplant candidates evaluated between January 1, 2000
and April 1, 2013 due to the suspicion of structural liver damage
such as liver ﬁbrosis secondary to congestive hepatopathy, previous
hepatitis or irreversible liver function abnormalities, and concom-
itant imaging abnormalities. Unfortunately, our current analysis
focused on the utilization of MELD scores that included only total
bilirubin, and we did not include direct bilirubin into our analysis
(1). It would be interesting, however, to study this parameter in a
subsequent analysis. Nevertheless, the impact of bilirubin and its
speciﬁc statistical weight within the composite MELD scores has
only been established for total bilirubin, and it will require ad-
justments if direct bilirubin will be used instead of total bilirubin.
We agree with Dr. Valentova and colleagues that elevated
MELD scores might reﬂect more severe comorbidities and
more advanced HF. However, in our cohort, we did not detect
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1811differences in the prevalence of diabetes mellitus or atrial ﬁbrilla-
tion. Of note, peak volume of oxygen use was lower (13.4  5.1
ml/min/kg vs. 11.5  3.7 ml/min/kg; p ¼ 0.0005) whereas the
Seattle Heart Failure Model score was higher in patients with
higher MELD scores (0.38  0.8 vs. 0.64  0.8; p ¼ 0.0087).
Therefore, it will require further prospective studies to characterize
the speciﬁc impact of the MELD scoring system for the prognostic
evaluation both before and after HTx. However, we have shown in
previous analyses that both mechanical unloading with left ven-
tricular assist devices (2) and HTx (3) lead to a decrease in MELD
scores. Most importantly, while the role and impact of pharma-
cologic strategies is unclear, we have shown that patients who
normalize MELD and MELD-XI (MELD Excluding INR)
scores after left ventricular assist device implantation have a better
prognosis following HTx than do patients with persistently
elevated MELD scores (2). Therefore, we suggest that the MELD
scoring system is a novel risk assessment tool for the character-
ization of patients with advanced HF.Tomoko S. Kato, MD, PhD
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2012;31:591–600.Is the J Wave or the
ST Slope Malignant.Figure 1 Cardiovascular Survival Plot According to ST Slope
Kaplan–Meier survival plot with cardiovascular death (CV) as the outcome for a
large clinic population of veterans divided by ST slope on a routine 10-s
electrocardiogram.or Neither?
Probably no group has done more to make sense of the current
confusion regarding early repolarization than our friends from Tel
Aviv. Although we agree with their logical conclusions in their
recent state-of-the-art paper (1), we would like to add our own
concerns regarding terminology and the risk of the electrocardio-
graphic (ECG) patterns they discuss.We believe that the current nomenclature provides a potentially
major cause of confusion (2). “Early repolarization” already has
both electrophysiological and ECG deﬁnitions. It is the electro-
physiological designation of phase 1 of the myocyte action po-
tential, and certainly in the United States, it is also an ECG
pattern characterized by normal variant ST-segment elevation.
The ﬁrst reports were from young African-American men (3).
Our Israeli colleagues were spared this problem because of the
lower prevalence of persons of African descent in their country. It
is important to note that most automated ECG programs today
make the statement of “early repolarization” based only on
ST-segment elevation, without detection of J-wave notches or
slurs. We adopted the terms “J-wave pattern/syndrome” in a
recent symposium in Journal of Electrocardiology to clarify this
distinction (4).
Furthermore, we have concerns whether any pattern of J waves or
slurs on a routine electrocardiogram from a stable patient is asso-
ciated with cardiovascular risk. In 2012, Uberoi et al. (5) reported
that the risk of common patterns of early repolarization in an
ambulatory population of 30,000 clinic patients with 8-year follow-
up was only due to associated Q waves or T-wave inversions. To
demonstrate the importance of the ST slope on prognosis, Figure 1
shows the Kaplan-Meier survival curves from the same population.
This ﬁgure demonstrates the risk of cardiovascular death associated
with ﬂat or downsloping ST segments in the inferior and lateral
leads, regardless of the presence of J waves.
Although we do not have J waves or slurs coded on the entire
sample, we have not found any risk in a subset (6). We recently
summarized the available studies dealing with prognosis (7) but
have concerns regarding the publication bias for positive studies
and the difﬁculty deciphering their methods for ECG coding (8).
In light of these ﬁndings, should an ECG pattern that has never
been shown to predict cardiovascular risk in any population
studies until at least 15 years of follow-up really be considered
“malignant”?
Our discussion is not meant to dismiss the large J waves and
slurs, particularly the dynamic forms that are an important feature
